Menu Search
Equities

ChromoGenics AB

384:BER

ChromoGenics AB

Actions
  • Price (EUR)0.858
  • Today's Change0.01 / 1.18%
  • Shares traded--
  • 1 Year change-4.67%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 20:50 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ChromoGenics AB is a Sweden-based company, which develops, manufactures and markets foil-based products with controllable optical properties and conducts related business. The Company’s primary product is ConverLight, which is an electrochromic glass with dynamic solar control properties. This glass enables control of light influx to tone down the light and energy admission in various parts of property or premises. The glass is suitable for new construction, reconstruction and renovation and offers ultraviolet protection that reduces risk of fading interiors. The Company distributes ConverLight to commercial installation companies in Sweden and Norway. The main shareholders in the Company are K-Svets Venture AB and New Energy Solutions II K/S.

  • Revenue in SEK (TTM)10.68m
  • Net income in SEK-53.03m
  • Incorporated2002
  • Employees34.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.